Switched on: Investing in the 'nuts and bolts' of artificial intelligence

Taking advantage of the 'fourth industrial revolution'

clock • 4 min read

Artificial intelligence (AI) is increasingly cropping up in the most unexpected of places, writes Chris Ford, manager of the Smith & Williamson Artificial Intelligence fund.

Just recently, it was the turn of the mighty McDonald's to announce it will be acquiring an Israeli AI business, Dynamic Yield Ltd, and trialling the use of artificial intelligence at its restaurants. Labelled "the fourth industrial revolution", AI and big data can have a truly staggering impact on companies' financial performance - but only if they know how to make the best use of it. It is one thing to capture data about customers, processes or some other part of a business, but it is quite another to be able to actually utilise it. Artificial intelligence - is the UK ready, will...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot